Trials / Terminated
TerminatedNCT00086632
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Unither Pharmaceuticals · Industry
- Sex
- Female
- Age
- 80 Years
- Healthy volunteers
- Not accepted
Summary
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients. Immunotherapy causes the body's defenses to react against cancer cells. The purpose of this research study is to determine if immunotherapy with oregovomab can create an immune response and enable the body to fight the disease and help ovarian cancer patients live longer. Patients with a possible diagnosis of ovarian cancer will be screened for study participation pre-surgery and, if eligible, will receive oregovomab during front-line chemotherapy treatment for ovarian cancer and quarterly for about a year following chemotherapy. Patients who experience disease progression will be discontinued from oregovomab therapy. Patients will also have urine, blood and tissue samples collected to assess the immune response to oregovomab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oregovomab |
Timeline
- Start date
- 2004-07-01
- Completion
- 2007-12-01
- First posted
- 2004-07-09
- Last updated
- 2007-12-18
Source: ClinicalTrials.gov record NCT00086632. Inclusion in this directory is not an endorsement.